Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b/2, Open-label Clinical Study to Determine Preliminary Safety and Efficacy of Alvocidib When Administered in Sequence After Decitabine in Patients With MDS

Trial Profile

A Phase 1b/2, Open-label Clinical Study to Determine Preliminary Safety and Efficacy of Alvocidib When Administered in Sequence After Decitabine in Patients With MDS

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 15 Nov 2018

At a glance

  • Drugs Alvocidib (Primary) ; Decitabine (Primary)
  • Indications Myelodysplastic syndromes
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms Zella 102
  • Sponsors Tolero Pharmaceuticals
  • Most Recent Events

    • 16 Oct 2018 According to a Tolero Pharmaceuticals media release, the first patient has been enrolled and dosed in this trial.
    • 16 Oct 2018 Status changed from not yet recruiting to recruiting, according to a Tolero Pharmaceuticals media release.
    • 25 Jul 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top